An Introduction to Nuclear Hormone Receptors
============================================

Nuclear hormone receptors are specialised transcription factors with commonalities of sequence and structure, which bind as homo- or heterodimers to specific consensus sequences of DNA (response elements) in the promoter region of particular target genes. They regulate (either promoting or repressing) transcription of these target genes in response to a variety of endogenous ligands. Endogenous agonists are hydrophobic entities which, when bound to the receptor promote conformational changes in the receptor to allow recruitment (or dissociation) of protein partners, generating a large multiprotein complex.

Two major subclasses of nuclear hormone receptors with identified endogenous agonists can be identified: steroid and non-steroid hormone receptors. Steroid hormone receptors function typically as dimeric entities and are thought to be resident outside the nucleus in the unliganded state in a complex with chaperone proteins, which are liberated upon agonist binding. Migration to the nucleus and interaction with other regulators of gene transcription, including RNA polymerase, acetyltransferases and deacetylases, allows gene transcription to be regulated. Non-steroid hormone receptors typically exhibit a greater distribution in the nucleus in the unliganded state and interact with other nuclear hormone receptors to form heterodimers, as well as with other regulators of gene transcription, leading to changes in gene transcription upon agonist binding.

Selectivity of gene regulation is brought about through interaction of nuclear hormone receptors with particular consensus sequences of DNA, which are arranged typically as repeats or inverted palindromes to allow accumulation of multiple transcription factors in the promoter regions of genes.
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1A. Thyroid Hormone Receptors
=============================

Overview
--------

Thyroid hormone receptors (TRs, nomenclature as agreed by NC-IUPHAR Committee on Nuclear Receptors, [@b3]) are nuclear hormone receptors of the NR1A family, with diverse roles regulating macronutrient metabolism, cognition and cardiovascular homeostasis. TRs are activated by thyroxine (T4) and thyroid hormone (T3). Once activated by a ligand, the receptor acts as a transcription factor either as a monomer, homodimer or heterodimer with members of the retinoid X receptor family. NH-3 has been described as an antagonist at TRs with modest selectivity for TRβ [@b4].

  ------------------------------ ---------------------------- ----------------------------------
  Nomenclature                   Thyroid hormone receptor-α   Thyroid hormone receptor-β
  Systematic nomenclature        NR1A1                        NR1A2
  HGNC, UniProt                  THRA, P10827                 THRB, P10828
  Rank order of potency          T3 \> T4                     T3 \> T4
  Selective agonists (p*K*~i~)   --                           GC-1 (p*K*~d~ 10.17) [@b2],[@b5]
  ------------------------------ ---------------------------- ----------------------------------

Comments
========

An interaction with integrin αVβ3 has been suggested to underlie plasma membrane localization of TRs and non-genomic signalling [@b1]. One splice variant, TRα~2~, lacks a functional DNA-binding domain and appears to act as a transcription suppressor.

Although radioligand binding assays have been described for these receptors, the radioligands are not commercially available.

1B. Retinoic acid receptors
===========================

Overview
--------

Retinoic acid receptors (nomenclature as agreed by NC-IUPHAR Committee on Nuclear Receptors, [@b8]) are nuclear hormone receptors of the NR1B family activated by the vitamin A-derived agonists all-trans-retinoic acid (ATRA) and 9-cis-retinoic acid, and the RAR-selective synthetic agonists TTNPB and adapalene.

  --------------------------------- ----------------------------------------------------- --------------------------------------------------------------------------- --------------------------
  Nomenclature                      Retinoic acid receptor-α                              Retinoic acid receptor-β                                                    Retinoic acid receptor-γ
  Systematic nomenclature           NR1B1                                                 NR1B2                                                                       NR1B3
  HGNC, UniProt                     RARA, P10276                                          RARB, P10826                                                                RARG, P13631
  Selective agonists (p*K*~i~)      Ro 40-6055 [@b7],[@b11],[@b18], BMS753 (8.7) [@b10]   AC261066 (pEC~50~ 7.9 -- 8.1) [@b15], AC55649 (pEC~50~ 6.5 -- 7.3) [@b15]   AHPN [@b16]
  Selective antagonists (p*K*~i~)   Ro 41-5253 (pIC~50~ 6.3 -- 7.2) [@b6],[@b12]          --                                                                          MM 11253 [@b13]
  --------------------------------- ----------------------------------------------------- --------------------------------------------------------------------------- --------------------------

Comments
========

Ro 41-5253 has been suggested to be a PPARγ agonist [@b17]. LE135 is an antagonist with selectivity for RARα and RARβ compared with RARγ [@b14]. [@b9] is a family-selective antagonist.

1C. Peroxisome proliferator-activated receptors
===============================================

Overview
--------

Peroxisome proliferator-activated receptors (PPARs, nomenclature as agreed by NC-IUPHAR Committee on Nuclear Receptors, [@b33]) are nuclear hormone receptors of the NR1C family, with diverse roles regulating lipid homeostasis, cellular differentiation, proliferation and the immune response. PPARs have many potential endogenous agonists [@b21],[@b33], including 15-deoxy-Δ12,14-PGJ2, prostacyclin (PGI2), many fatty acids and their oxidation products, lysophosphatidic acid (LPA) [@b32], 13-HODE, 15S-HETE, Paz-PC, azelaoyl-PAF and leukotriene B4 (LTB4). bezafibrate acts as a non-selective agonist for the PPAR family [@b41]. These receptors also bind hypolipidaemic drugs (PPARα) and anti-diabetic thiazolidinediones (PPARγ), as well as many non-steroidal anti-inflammatory drugs, such as sulindac and indomethacin. Once activated by a ligand, the receptor forms a heterodimer with members of the retinoid X receptor family and can act as a transcription factor. Although radioligand binding assays have been described for all three receptors, the radioligands are not commercially available. Commonly, receptor occupancy studies are conducted using fluorescent ligands and truncated forms of the receptor limited to the ligand binding domain.

  --------------------------------- ----------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                      Peroxisome proliferator-activated receptor-α                                                                            Peroxisome proliferator-activated receptor-β/δ                       Peroxisome proliferator-activated receptor-γ
  Systematic nomenclature           NR1C1                                                                                                                   NR1C2                                                                NR1C3
  HGNC, UniProt                     PPARA, Q07869                                                                                                           PPARD, Q03181                                                        PPARG, P37231
  Selective agonists (p*K*~i~)      ciprofibrate, GW7647 (pEC~50~ 8.2) [@b22],[@b23], CP-775146 (pEC~50~ 7.3) [@b28], pirinixic acid (pEC~50~ 5.3) [@b41]   GW501516 (pEC~50~ 9.0) [@b35], GW0742X (pIC~50~ 9.0) [@b25],[@b39]   rosiglitazone (p*K*~d~ 7.4) [@b27],[@b31],[@b44], GW1929 (8.8) [@b22], CDDO (Partial agonist) (8.0) [@b40], troglitazone (5.8) [@b19], ciglitazone (pEC~50~ 4.6) [@b27], troglitazone (pIC~50~ 6.3) [@b27],[@b44], pioglitazone (pIC~50~ 6.2) [@b27],[@b37],[@b44]
  Selective antagonists (p*K*~i~)   GW6471 (pIC~50~ 6.6) [@b42]                                                                                             GSK0660 (pIC~50~ 6.5) [@b38]                                         T0070907 (9.0) [@b29], CDDO-Me (6.9) [@b40], GW9662 (Irreversible inhibition) (pIC~50~ 8.1) [@b30]
  --------------------------------- ----------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

As with the estrogen receptor antagonists, many agents show tissue-selective efficacy (*e.g*. [@b20],[@b34],[@b36]). Agonists with mixed activity at PPARα and PPARγ have also been described (*e.g* [@b24],[@b26],[@b43]).

1D. Rev-Erb receptors
=====================

Overview
--------

Rev-erb receptors (nomenclature as agreed by NC-IUPHAR committee on nuclear hormone receptors [@b45]) have yet to be officially paired with an endogenous ligand, but are thought to be activated by heme.

  --------------------------------- ------------------------------------------------------------ --------------------------------
  Nomenclature                      Rev-Erb-α                                                    Rev-Erb-β
  Systematic nomenclature           NR1D1                                                        NR1D2
  HGNC, UniProt                     NR1D1, P20393                                                NR1D2, Q14995
  Endogenous agonists (p*K*~i~)     heme (Selective) [@b48],[@b49]                               heme (Selective) [@b48],[@b49]
  Selective agonists (p*K*~i~)      GSK4112 (pEC~50~ 6.4) [@b46], GSK4112 (pIC~50~ 5.6) [@b47]   --
  Selective antagonists (p*K*~i~)   SR8278 (pIC~50~ 6.5) [@b47]                                  --
  --------------------------------- ------------------------------------------------------------ --------------------------------

1F. Retinoic acid-related orphans
=================================

Overview
--------

Retinoic acid receptor-related orphan receptors (ROR, nomenclature as agreed by NC-IUPHAR Committee on Nuclear Receptors, [@b50]) have yet to be assigned a definitive endogenous ligand, although RORα may be synthesized with a 'captured' agonist such as cholesterol [@b52],[@b53].

  ------------------------------- ----------------------------------------------------------------- ------------------------------- -------------------------------
  Nomenclature                    RAR-related orphan receptor-α                                     RAR-related orphan receptor-β   RAR-related orphan receptor-γ
  Systematic nomenclature         NR1F1                                                             NR1F2                           NR1F3
  HGNC, UniProt                   RORA, P35398                                                      RORB, Q92753                    RORC, P51449
  Endogenous agonists (p*K*~i~)   cholesterol (Selective) [@b53],[@b54]                             --                              --
  Selective agonists (p*K*~i~)    7-hydroxycholesterol [@b51], cholesterol sulphate [@b51],[@b53]   --                              --
  ------------------------------- ----------------------------------------------------------------- ------------------------------- -------------------------------

Comments
========

all-trans-retinoic acid shows selectivity for RORβ within the ROR family [@b55]. RORα has been suggested to be a nuclear receptor responding to melatonin [@b56].

1H. Liver X receptor-like receptors
===================================

Overview
--------

Liver X and farnesoid X receptors (LXR and FXR, nomenclature as agreed by NC-IUPHAR Committee on Nuclear Receptors, [@b62]) are members of a steroid analogue-activated nuclear receptor subfamily (ENSFM00500000269785), which form heterodimers with members of the retinoid X receptor family. Endogenous ligands for LXRs include hydroxycholesterols (OHC), while FXRs appear to be activated by bile acids.

  --------------------------------- ------------------------------------------------------------------------------------------ ----------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                      Farnesoid X receptor                                                                       Farnesoid X receptor-β                    Liver X receptor-α                                                                                                                Liver X receptor-β
  Systematic nomenclature           NR1H4                                                                                      NR1H5                                     NR1H3                                                                                                                             NR1H2
  HGNC, UniProt                     NR1H4, Q96RI1                                                                              NR1H5P, -                                 NR1H3, Q13133                                                                                                                     NR1H2, P55055
  Potency order                     chenodeoxycholic acid \> lithocholic acid, deoxycholic acid [@b60],[@b64]                  --                                        20S-hydroxycholesterol, 22R-hydroxycholesterol, 24(S)-hydroxycholesterol \> 25-hydroxycholesterol, 27-hydroxycholesterol [@b59]   20S-hydroxycholesterol, 22R-hydroxycholesterol, 24(S)-hydroxycholesterol \> 25-hydroxycholesterol, 27-hydroxycholesterol [@b59]
  Selective agonists (p*K*~i~)      GW4064 (pEC~50~ 7.8) [@b61], ECDCA (pEC~50~ 7.0) [@b65], fexaramine (pEC~50~ 6.6) [@b58]   --                                        --                                                                                                                                --
  Selective antagonists (p*K*~i~)   guggulsterone (pIC~50~ 5.7 -- 6.0) [@b67]                                                  --                                        --                                                                                                                                --
  Endogenous agonists (p*K*~i~)     --                                                                                         lanosterol (pEC~50~ 6.0 - Mouse) [@b63]   --                                                                                                                                --
  --------------------------------- ------------------------------------------------------------------------------------------ ----------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------

Comments
========

T0901317 [@b66] and GW3965 [@b57] are synthetic agonists acting at both LXRα and LXRβ with less than 10-fold selectivity. NR1H5P (FXRβ) is a pseudogene in man, but active in the mouse.

1I. Vitamin D receptor-like receptors
=====================================

Overview
--------

Vitamin D (VDR), Pregnane X (PXR) and Constitutive Androstane (CAR) receptors (nomenclature as agreed by NC-IUPHAR Committee on Nuclear Receptors, [@b79]) are members of the NR1I family of nuclear receptors, which form heterodimers with members of the retinoid X receptor family. PXR and CAR are activated by a range of exogenous compounds, with no established endogenous physiological agonists, although high concentrations of bile acids and bile pigments activate PXR and CAR[@b79].

  --------------------------------- ------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                      Vitamin D receptor                                            Pregnane X receptor                                                                                                                                                 Constitutive androstane receptor
  Systematic nomenclature           NR1I1                                                         NR1I2                                                                                                                                                               NR1I3
  HGNC, UniProt                     VDR, P11473                                                   NR1I2, O75469                                                                                                                                                       NR1I3, Q14994
  Endogenous agonists (p*K*~i~)     1,25-dihydroxyvitamin D3 (p*K*~d~ 8.9 -- 9.2) [@b68],[@b71]   17β-estradiol (Selective) [@b74]                                                                                                                                    --
  Selective agonists (p*K*~i~)      EB1089 (p*K*~d~ 9.57) [@b70],[@b84]                           hyperforin (pEC~50~ 7.6) [@b80],[@b83], rifampicin (pEC~50~ 5.5 -- 6.0) [@b69],[@b76], lovastatin (pEC~50~ 5.3 -- 6.0) [@b76], pregnanedione (pIC~50~ 6.4) [@b74]   TCPOBOP (pEC~50~ 7.7 - Mouse) [@b82], CITCO (pEC~50~ 7.3) [@b77]
  Selective antagonists (p*K*~i~)   TEI-9647 [@b78], ZK159222 (pIC~50~ 7.5) [@b72],[@b73]         --                                                                                                                                                                  --
  Comment                           --                                                            --                                                                                                                                                                  clotrimazole [@b81] and T0901317 [@b75] although acting at other sites, function as antagonists of the constitutive androstane receptor
  --------------------------------- ------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------

2A. Hepatocyte nuclear factor-4 receptors
=========================================

Overview
--------

Hepatocyte nuclear factor-4 receptors (nomenclature as agreed by NC-IUPHAR committee on nuclear hormone receptors [@b85]) have yet to be officially paired with an endogenous ligand, although linoleic acid has been described to activate HNF4α receptors.

  --------------------------------- ---------------------------------- -------------------------------
  Nomenclature                      Hepatocyte nuclear factor-4-α      Hepatocyte nuclear factor-4-γ
  Systematic nomenclature           NR2A1                              NR2A2
  HGNC, UniProt                     HNF4A, P41235                      HNF4G, Q14541
  Endogenous agonists (p*K*~i~)     linoleic acid (Selective) [@b87]   --
  Selective antagonists (p*K*~i~)   BI6015 [@b86]                      --
  --------------------------------- ---------------------------------- -------------------------------

2B. Retinoid X receptors
========================

Overview
--------

Retinoid X receptors (nomenclature as agreed by NC-IUPHAR Committee on Nuclear Receptors, [@b90]) are NR2B family members activated by 9-cis-retinoic acid and the RXR-selective agonists bexarotene and LG100268, sometimes referred to as rexinoids. UVI3003 [@b93] and HX531 [@b89] have been described as a pan-RXR antagonists. These receptors form RXR--RAR heterodimers and RXR--RXR homodimers [@b88],[@b92].

  ------------------------------ ----------------------------- ----------------------- -----------------------
  Nomenclature                   Retinoid X receptor-α         Retinoid X receptor-β   Retinoid X receptor-γ
  Systematic nomenclature        NR2B1                         NR2B2                   NR2B3
  HGNC, UniProt                  RXRA, P19793                  RXRB, P28702            RXRG, P48443
  Selective agonists (p*K*~i~)   CD3254 (pIC~50~ 8.5) [@b91]   --                      --
  ------------------------------ ----------------------------- ----------------------- -----------------------

2C. Testicular receptors
========================

Overview
--------

Testicular receptors (nomenclature as agreed by NC-IUPHAR committee on nuclear hormone receptors [@b94]) have yet to be officially paired with an endogenous ligand, although testicular receptor 4 has been reported to respond to retinoids.

  ------------------------------- ------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------
  Nomenclature                    Testicular receptor 2                                                                                               Testicular receptor 4
  Systematic nomenclature         NR2C1                                                                                                               NR2C2
  HGNC, UniProt                   NR2C1, P13056                                                                                                       NR2C2, P49116
  Endogenous agonists (p*K*~i~)   --                                                                                                                  all-trans-retinoic acid (Selective) [@b96], retinol (Selective) [@b96]
  Comment                         Forms a heterodimer with TR4; gene disruption appears without effect on testicular development or function [@b95]   Forms a heterodimer with TR2
  ------------------------------- ------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------

2E. Tailless-like receptors
===========================

Overview
--------

Tailless-like receptors (nomenclature as agreed by NC-IUPHAR committee on nuclear hormone receptors [@b97]) have yet to be officially paired with an endogenous ligand.

  ------------------------- ----------------------------------------------------------------------------- ---------------
  Nomenclature              TLX                                                                           PNR
  Systematic nomenclature   NR2E1                                                                         NR2E3
  HGNC, UniProt             NR2E1, Q9Y466                                                                 NR2E3, Q9Y5X4
  Comment                   Gene disruption is associated with abnormal brain development [@b98],[@b99]   --
  ------------------------- ----------------------------------------------------------------------------- ---------------

2F. COUP-TF-like receptors
==========================

Overview
--------

COUP-TF-like receptors (nomenclature as agreed by NC-IUPHAR committee on nuclear hormone receptors [@b100]) have yet to be officially paired with an endogenous ligand.

  ------------------------- ----------------------------------------------- ------------------------------------------------- -------------------------------------------------
  Nomenclature              COUP-TF1                                        COUP-TF2                                          V-erbA-related gene
  Systematic nomenclature   NR2F1                                           NR2F2                                             NR2F6
  HGNC, UniProt             NR2F1, P10589                                   NR2F2, P24468                                     NR2F6, P10588
  Comment                   Gene disruption is perinatally lethal [@b102]   Gene disruption is embryonically lethal [@b101]   Gene disruption impairs CNS development [@b103]
  ------------------------- ----------------------------------------------- ------------------------------------------------- -------------------------------------------------

3B. Estrogen-related receptors
==============================

Overview
--------

Estrogen-related receptors (nomenclature as agreed by NC-IUPHAR committee on nuclear hormone receptors [@b104]) have yet to be officially paired with an endogenous ligand.

  ------------------------- -------------------------------------------------------------------------------------------------------------------------------- ----------------------------------- -----------------------------------
  Nomenclature              Estrogen-related receptor-α                                                                                                      Estrogen-related receptor-β         Estrogen-related receptor-γ
  Systematic nomenclature   NR3B1                                                                                                                            NR3B2                               NR3B3
  HGNC, UniProt             ESRRA, P11474                                                                                                                    ESRRB, O95718                       ESRRG, P62508
  Comment                   Activated by some dietary flavonoids [@b105]; activated by the synthetic agonist GSK4716 [@b108] and blocked by XCT790 [@b106]   May be activated by DY131 [@b107]   May be activated by DY131 [@b107]
  ------------------------- -------------------------------------------------------------------------------------------------------------------------------- ----------------------------------- -----------------------------------

4A. Nerve growth factor IB-like receptors
=========================================

Overview
--------

Nerve growth factor IB-like receptors (nomenclature as agreed by NC-IUPHAR committee on nuclear hormone receptors [@b110]) have yet to be officially paired with an endogenous ligand.

  ------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ----------------------------------
  Nomenclature              Nerve Growth factor IB                                                                                                                                                                    Nuclear receptor related 1   Neuron-derived orphan receptor 1
  Systematic nomenclature   NR4A1                                                                                                                                                                                     NR4A2                        NR4A3
  HGNC, UniProt             NR4A1, P22736                                                                                                                                                                             NR4A2, P43354                NR4A3, Q92570
  Comment                   An endogenous agonist, cytosporone B, has been described [@b113], although structural analysis and molecular modelling has not identified a ligand binding site [@b109],[@b111],[@b112]   --                           --
  ------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ----------------------------------

5A. Fushi tarazu F1-like receptors
==================================

Overview
--------

Fushi tarazu F1-like receptors (nomenclature as agreed by NC-IUPHAR committee on nuclear hormone receptors [@b114]) have yet to be officially paired with an endogenous ligand.

  ------------------------- -------------------------------------------------------------------- --------------------------
  Nomenclature              Steroidogenic factor 1                                               Liver receptor homolog-1
  Systematic nomenclature   NR5A1                                                                NR5A2
  HGNC, UniProt             NR5A1, Q13285                                                        NR5A2, O00482
  Comment                   Reported to be inhibited by AC45594 [@b115] and SID7969543 [@b116]   --
  ------------------------- -------------------------------------------------------------------- --------------------------

6A. Germ cell nuclear factor receptors
======================================

Overview
--------

Germ cell nuclear factor receptors (nomenclature as agreed by NC-IUPHAR committee on nuclear hormone receptors [@b117]) have yet to be officially paired with an endogenous ligand.

  ------------------------- --------------------------
  Nomenclature              Germ cell nuclear factor
  Systematic nomenclature   NR6A1
  HGNC, UniProt             NR6A1, Q15406
  ------------------------- --------------------------

0B. DAX-like receptors
======================

Overview
--------

Dax-like receptors (nomenclature as agreed by NC-IUPHAR committee on nuclear hormone receptors [@b118]) have yet to be officially paired with an endogenous ligand.

  ------------------------- --------------- ---------------
  Nomenclature              DAX1            SHP
  Systematic nomenclature   NR0B1           NR0B2
  HGNC, UniProt             NR0B1, P51843   NR0B2, Q15466
  ------------------------- --------------- ---------------

Steroid hormone receptors
=========================

Overview
--------

Steroid hormone receptors (nomenclature as agreed by NC-IUPHAR Committee on Nuclear Receptors, [@b120],[@b132]) are nuclear hormone receptors of the NR3 class, with endogenous agonists that may be divided into 3-hydroxysteroids (estrone and 17β-estradiol) and 3-ketosteroids (dihydrotestosterone \[DHT\], aldosterone, cortisol, corticosterone, progesterone and testosterone). These receptors exist as dimers coupled with chaperone molecules (such as hsp90 (HSP90AB1, P08238) and immunophilin FKBP52:FKBP4, Q02790), which are shed on binding the steroid hormone. Although rapid signalling phenomena are observed [@b130],[@b138], the principal signalling cascade appears to involve binding of the activated receptors to nuclear hormone response elements of the genome, with a 15-nucleotide consensus sequence AGAACAnnnTGTTCT (*i.e.* an inverted palindrome) as homo- or heterodimers. They also affect transcription by protein--protein interactions with other transcription factors, such as activator protein 1 (AP-1) and nuclear factor κB (NF-κB). Splice variants of each of these receptors can form functional or non-functional monomers that can dimerize to form functional or non-functional receptors. For example, alternative splicing of PR mRNA produces A and B monomers that combine to produce functional AA, AB and BB receptors with distinct characteristics [@b148].

A 7TM receptor responsive to estrogen (GPER1, Q99527, also known as GPR30, see [@b137]) has been described. Human orthologues of 7TM 'membrane progestin receptors' (PAQR7, PAQR8 and PAQR5), initially discovered in fish [@b151],[@b152], appear to localize to intracellular membranes and respond to 'non-genomic' progesterone analogues independently of G proteins [@b142].

3A. Estrogen receptors
======================

  --------------------------------- ------------------------------------------- ----------------------------------------------------------------------------------------------------
  Nomenclature                      Estrogen receptor-α                         Estrogen receptor-β
  Systematic nomenclature           NR3A1                                       NR3A2
  HGNC, UniProt                     ESR1, P03372                                ESR2, Q92731
  Selective agonists (p*K*~i~)      PPT (9.64) [@b128],[@b143]                  ERB 041 [@b133], diarylpropionitril (8.6) [@b135],[@b143], WAY200070 (pIC~50~ 8.52 -- 9.0) [@b133]
  Selective antagonists (p*K*~i~)   methyl-piperidino-pyrazole (8.57) [@b145]   PHTPP [@b119], R,R-THC (8.44) [@b134],[@b146]
  --------------------------------- ------------------------------------------- ----------------------------------------------------------------------------------------------------

Comments
========

R,R-THC exhibits partial agonist activity at ERα [@b134],[@b146]. Estrogen receptors may be blocked non-selectively by tamoxifen and raloxifene and labelled by \[3H\]17β-estradiol and \[3H\]tamoxifen. Many agents thought initially to be antagonists at estrogen receptors appear to have tissue-specific efficacy (*e.g*. tamoxifen is an antagonist at estrogen receptors in the breast, but is an agonist at estrogen receptors in the uterus), hence the descriptor SERM (selective estrogen receptor modulator) or SnuRM (selective nuclear receptor modulator). Y134 has been suggested to be an ERα-selective estrogen receptor modulator [@b136].

3C. 3-Ketosteroid receptors
===========================

  --------------------------------- --------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------------------ -------------------------------------
  Nomenclature                      Androgen receptor                                                                                                           Glucocorticoid receptor                                             Mineralocorticoid receptor                                                     Progesterone receptor
  Systematic nomenclature           NR3C4                                                                                                                       NR3C1                                                               NR3C2                                                                          NR3C3
  HGNC, UniProt                     AR, P10275                                                                                                                  NR3C1, P04150                                                       NR3C2, P08235                                                                  PGR, P06401
  Rank order of potency             dihydrotestosterone\>testosterone                                                                                           cortisol,corticosterone\>\>aldosterone,deoxycortisone [@b139]       corticosterone,cortisol,aldosterone,progesterone [@b139]                       progesterone
  Endogenous agonists (p*K*~i~)     dihydrotestosterone (p*K*~d~ 9.3) [@b147]                                                                                   --                                                                  aldosterone (Selective) (pIC~50~ 9.8 -- 10.0) [@b126],[@b139]                  progesterone (Selective)
  Selective agonists (p*K*~i~)      methyltrienolone (pEC~50~ \< 5.0) [@b149], mibolerone (pIC~50~ 8.96) [@b124]                                                fluticasone, RU26988, RU28362                                       --                                                                             levonorgestrel [@b140], ORG2058
  Selective antagonists (p*K*~i~)   hydroxyflutamide (pEC~50~ 6.6) [@b149], PF0998425 (pIC~50~ 7.1 -- 7.5) [@b131], nilutamide (pIC~50~ 7.07 -- 7.12) [@b141]   onapristone, ZK112993, mifepristone (p*K*~d~ 9.4) [@b125],[@b139]   onapristone, RU28318, ZK112993, eplerenone (pIC~50~ 1.0) [@b121],[@b127]       mifepristone, onapristone, ZK112993
  Radioligands (*K*~d~)             \[3H\]dihydrotestosterone (Agonist), \[3H\]mibolerone (Agonist), \[3H\]R1881 (Agonist)                                      \[3H\]dexamethasone (Agonist)                                       \[3H\]aldosterone (Agonist) (3x10^-10^ -- 4x10^-10^ M - Rat) [@b123],[@b144]   \[3H\]ORG2058 (Agonist)
  --------------------------------- --------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------------------ -------------------------------------

Comments
========

\[3H\]dexamethasone also binds to MR *in vitro*. PR antagonists have been suggested to subdivide into Type I (*e.g.* onapristone) and Type II (*e.g*. ZK112993) groups. These groups appear to promote binding of PR to DNA with different efficacies and evoke distinct conformational changes in the receptor, leading to a transcription-neutral complex [@b122],[@b129]. Mutations in AR underlie testicular feminization and androgen insensibility syndromes, spinal and bulbar muscular atrophy (Kennedy\'s disease).
